Bay City Capital
Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Business Model:
Revenue: $8.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Bay City Capital Information
Geographic Data
Address: 750 Battery St
City: San Francisco
State: CA
Zip: 94111
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2M
Social
Twitter
Linkedin
Crunchbase
Metrics
7,558,103Website Global Rank
502Website Monthly Traffic
Twitter Followers
Description
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition and agribusiness sector fund.
Contact Phone:
+14156763830
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2011 | Conatus Pharmaceuticals | Series B | 0 |
| 10/2013 | Galecto | Series B | 6.3M |
| 8/2003 | CymaBay Therapeutics | Series A | 27M |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 5/2017 | Xeris Pharmaceuticals | Series C | 0 |
| 7/2016 | Vtesse | Series A | 17M |
| 8/2000 | Intarcia Therapeutics | Venture Round | - |
| 1/2004 | PTC Therapeutics | Series E | 35M |
| 9/2000 | Senomyx | Series B | 10M |
| 10/2016 | Bridge Medicines | Venture Round | - |
| 6/2017 | Twist Bioscience | Venture Round | 27M |
| 10/2010 | IDEV Technologies | Series D | 46M |
| 7/2004 | EnteroMedics | Series A | - |
| 6/2009 | Hyperion Therapeutics | Series C | 60M |
| 4/2009 | Sunesis Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2013 | Dermira | Series B | 35M |
| 3/2007 | Phenomix | Series C | 55M |
| 3/2010 | Ion Torrent | Series C | 37.1M |
| 4/2014 | Madrigal Pharmaceuticals | Post-IPO Equity | - |
| 11/1997 | Maxia Pharmaceuticals | Venture Round | - |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 11/2000 | Helios Health | Venture Round | 0 |
| 9/2001 | PTC Therapeutics | Series D | 0 |
| 1/2014 | Fabric Genomics (formerly Omicia) | Series A | 6.8M |
| 8/2005 | Protez Pharmaceuticals | Series B | 15M |
| 10/2009 | Aviir | Venture Round | 1M |
| 6/2003 | Phenomix | Series A | 11.6M |
| 1/2006 | MAP Pharmaceuticals | Series C | 25.2M |
| 9/2004 | MAP Pharmaceuticals | Series B | 30M |
| 12/2008 | Aviir | Venture Round | 7.8M |
| 1/1998 | Pharminex | Venture Round | - |
| 6/2013 | Aviir | Series B | 10M |
| 9/2007 | Aviir | Series B | 11.3M |
| 1/1999 | LJL Biosystems | Post-IPO Equity | - |
| 1/2010 | Aviir | Venture Round | 4.2M |
| 10/2005 | Radiant Medical | Venture Round | 36M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 11/2009 | Calypso Medical | Series E | 50M |
| 9/2006 | NuPathe | Series A | 15M |
| 10/2003 | Reliant Pharmaceuticals | Series D | 115M |
| 1/2016 | Imara | Seed Round | 800k |
| 11/2012 | Ascendancy | Venture Round | - |
| 3/2007 | MAP Pharmaceuticals | Series D | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 7/2012 | GenturaDx | Series C | 21M |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 12/2011 | Aviir | Venture Round | 10M |
| 3/2008 | Aviir | Venture Round | 1.5M |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 2/2012 | Altheos | Series A | 12.5M |
| 9/2013 | Civitas Therapeutics | Series B | 0 |
| 6/2004 | PTC Therapeutics | Series E | 0 |
| 7/2004 | Phenomix | Series A | 2M |
| 4/2010 | Altheos | Series A | 20M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 3/2013 | Nabsys | Series D | 35M |
| 3/2019 | Imara | Series B | 0 |
| 2/2007 | PTC Therapeutics | Series F | 10M |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 4/2016 | Imara | Series A | 31M |
| 10/2011 | Dermira | Series A | 42M |
| 10/2013 | Merus | Series B | 42.2M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 7/2011 | Nevro | Series B | 58M |
| 4/2015 | Merus | Series C | 79.1M |
| 10/2009 | Epizyme | Series B | 32M |
| 10/2002 | Pharmion | Venture Round | 40M |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 9/2008 | Nevro | Series A | 21.8M |
| 8/2014 | Dermira | Series C | 51M |
| 5/2007 | Conatus Pharmaceuticals | Series A | 22M |
| 3/2002 | Phenomix | Series A | 12M |
| 1/2015 | Vtesse | Series A | 25M |
| 3/2013 | Nevro | Series C | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 3/2020 | Xilio Therapeutics | Series B | 100.5M |
| 11/2018 | NextCure | Series B | 93M |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 11/2020 | Bridge Medicines | Equity | 10M |
| 2/2008 | Cadence Pharmaceuticals | Post-IPO Equity | - |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 2/2013 | Aviir | Series B | 10M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 6/2002 | Itamar Medical | Venture Round | - |
| 4/2005 | Phenomix | Series B | 20M |
| 7/2008 | NuPathe | Series B | 30M |
| 3/2008 | BrainCells | Series B | 30M |
| 10/2013 | PharmAkea | Series A | 10M |
| 12/2014 | Interleukin Genetics | Post-IPO Equity | 5M |
| 6/2011 | Aviir | Venture Round | 3M |
| 1/2009 | Vivaldi Biosciences | Series A | 23M |
| 10/2013 | Cydan | Venture Round | 10M |
| 3/2009 | VIA Pharmaceuticals | Debt Financing | 10M |
| 4/2012 | Thermogenesis | Post-IPO Equity | - |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 10/2017 | Gritstone Bio | Venture Round | - |
| 12/1997 | Chemdex | Seed Round | - |
| 3/2008 | IDEV Technologies | Series C | 14.4M |
| 11/2002 | Pathway Diagnostics | Venture Round | - |
| 5/2013 | Interleukin Genetics | Post-IPO Equity | 12M |
| 3/2000 | AquaBounty Technologies | Venture Round | - |
| 7/2005 | BrainCells | Series A | 0 |
| 4/2000 | Ingenuity Systems | Venture Round | - |
| 3/2009 | Accriva Diagnostics | Venture Round | - |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 3/1999 | VNUS Medical Technologies | Venture Round | - |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 8/2007 | Presidio Pharmaceuticals | Series B | 26M |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 12/2002 | Bioren | Seed Round | - |
| 8/2000 | Epocrates | Series B | 35M |
| 8/2002 | Epocrates | Series C | - |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 5/2007 | Vivaldi Biosciences | Series A | 2M |
| 10/2014 | SynGen | Venture Round | - |
| 4/2012 | SynGen | Series A | 5M |
| 1/2018 | Oculis | Series B | 20.5M |
| 1/2002 | BioSeek | Venture Round | - |
| 2/2002 | Syntonix Pharmaceuticals | Series B | 35.8M |
| 11/2000 | Panomics | Seed Round | - |
| 1/2010 | Merus | Series B | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 1/2008 | Aragon Surgical | Series B | 25M |
| 3/2002 | Reliant Pharmaceuticals | Series C | 160M |
| 9/2007 | Aciex Therapeutics | Series A | - |
| 1/1999 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 11/2020 | Bridge Medicines | Venture Round | 0 |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 3/2020 | Xilio Therapeutics | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 11/2018 | NextCure | Series B | 0 |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 1/2018 | Oculis | Series B | 0 |
| 10/2017 | Gritstone Bio | Venture Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
